Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 317-326 , June 2007

Prevention of type 2 diabetes: A review

  • A. Hussain

      Affiliations

    • Department of General Practice and Community Medicine, University of Oslo, Post Box 1130 Blindern, N-0318 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22850641; fax: +47 22850672.
    • ,
  • B. Claussen

      Affiliations

    • Department of General Practice and Community Medicine, University of Oslo, Post Box 1130 Blindern, N-0318 Oslo, Norway
    • ,
  • A. Ramachandran

      Affiliations

    • Diabetes Research Centre & M.V. Hospital for Diabetes, WHO Collaborating Centre for Research, Education and Training in Diabetes, No. 4, Main Road, Royapuram, Chennai 600013, India
    • ,
  • R. Williams

      Affiliations

    • School of Medicine, University of Wales, Swansea SA2 8PP, UK

Received 16 May 2006 ,Accepted 19 September 2006.

References 

  1. King H, Rewers M. Diabetes in adults is now a Third World problem. The WHO Ad Hoc Diabetes Reporting Group. Bull. World Health Organ. 1991;69:643–648
  2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diab. Care. 1998;21:1414–1431
  3. Centres for Disease Control. National Diabetes Fact Sheet, 2002. http://www.cdc.gov/diabetes/pubs/factsheet.htm.
  4. Eriksson J, Lindstrom J, Tuomiletho J. Potential for the prevention of type 2 diabetes. Br. Med. Bull. 2001;60:183–199
  5. Ludwig DS, Ebbeling C. Type 2 diabetes mellitus in children: primary care and public health considerations. JAMA. 2001;286:1427–1430
  6. L. Ritchie, S. Ivey, M. Masch, G. Woodward-Lopez, J.P. Ikeda, P.B. Crawford, Pediatric Overweight: a Review of the Literature. Conducted by the Center for Weight and Health, University of California, Berkeley. Prepared for the California Department of Health Services, Childhood Obesity Prevention Initiative, 2001. http://www.nature.berkley.edu/cwh/PDFs/Full-COPI-secure.pfd.
  7. Arita Y, Kihara S, Ouchi N, Takashi M, Maeda K, Mivagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999;257:79–83
  8. Nemet D, Wang P, Funahashi T, Matsuzawa Y, Tanaka S, Engelman L, et al. Adipocytokines, body composition and fitness in children. Pediatr. Res. 2003;53:148–152
  9. McGarry JD. Banting Lecture, 2001, Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes. 2002;51:7–18
  10. Blair SN, Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: current evidence and research issues. Med. Sci. Sports Exerc. 1999;31:646–662
  11. Vuori I. Health benefits of physical activity with special reference to interaction with diet. Diabetes. 1995;44:1010–1020
  12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002;346:393–403
  13. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia. 1991;34:891–898
  14. Tuomiletho J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350
  15. Gutin B, Barbeau P, Owens S, Lemmon CR, Bauman M, Allison J, et al. Effects of exercise intensity on cardiovascular fitness, total body composition, and visceral adiposity of obese adolescents. Am. J. Clin. Nutr. 2002;75:818–826
  16. Abate N, Chandalia M. Ethnicity and type 2 diabetes: focus on Asian Indians. J. Diab. Complications. 2001;15:320–327
  17. Vuori I. Health benefits of physical activity with special reference to interaction with diet. Diabetes. 1995;44:1010–1020
  18. Sherwood NE, Jeffery RW, French SA, Hannan PJ, Murray DM. Predictors of weight gain in the Pound of Prevention study. Int. J. Obes. Relat. Metab. Disord. 2000;24:395–403
  19. Lluch A, Herbeth B, Mejean L, Siest G. Dietary intakes, eating style and overweight in the Stanislas Family Study. Int. J. Obes. Relat. Metab. Disord. 2000;24:1493–1499
  20. Reaven GM. Diet and syndrome X. Curr. Atheroscler Rep. 2000;2:503–507
  21. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care. 2003;26:S51–S61
  22. International Diabetes Federation. Consensus on the Aetiology of Type 2 Diabetes Mellitus. Colombo, Sri Lanka. June 6–7, 2002. http://www.idf.org/home/index.cfm?node=444
  23. Veening MA, Van Weisenbruch MM, Delemarre-Van De Waal HA. Glucose tolerance, insulin sensitivity, and insulin secretion in children born small for gestational age. J. Clin. Endocrinol. Metab. 2002;87:4657–4661
  24. Dabelea D, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. Diab. Care. 1999;22:944–950
  25. Li C, Johnson MS, Goran MI. Effects of low birth weight on insulin resistance syndrome in Caucasian and African–American children. Diab. Care. 2001;24:2035–2042
  26. Innes KE, Byers TE, Marshall JA, Baron A, Orleans M, Hamman RF. Association of a woman's own birth weight with subsequent risk for gestational diabetes. JAMA. 2002;287:2534–2541
  27. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br. Med. Bull. 2001;60:5–20
  28. Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”?. Am. J. Hum. Genet. 1962;14:353–362
  29. Strauss RS. Effects of the intrauterine environment on childhood growth. Br. Med. Bull. 1997;53:81–95
  30. Jovanovic L. A tincture of time does not turn the tide: type 2 diabetes trends in offspring of type 2 diabetic mothers. Diab. Care. 2000;23:1219–1220
  31. Van Assche FA, Holemanszka K, Aerts L. Long-term consequences for offspring of diabetes during pregnancy. Br. Med. Bull. 2001;60:173–182
  32. Rosenbloom A. Fetal growth, adrenocortical function and the risk for type 2 diabetes. Pediatr. Diab. 2000;1:150–154
  33. Ananth C, Wen S. Trends in fetal growth among singleton gestations in the United States and Canada, 1985 through 1988. Semin. Perinatol. 2002;26:260–267
  34. Kramer MS, Morin I, Yang H, Platt RW, Usher R, McNamara H, et al. Why are babies getting bigger? Temporal trends in fetal growth and its determinants. J. Pediatr. 2002;141:538–542
  35. Dyck RF, Klomp H, Tan L. From “thrifty genotype” to “hefty fetal phenotype”: the relationship between high birthweight and diabetes in Saskatchewan Registered Indians. Can. J. Public Health. 2001;92:340–344
  36. Wei JN, Sung FC, Li CY, Chang CH, Lin RS, Lin CC, et al. Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan. Diabetes Care. 2003;26:343–348
  37. Lindsay RS, Hanson RL, Bennett PH, Knowler WC. Secular trends in birth weight, BMI, and diabetes in the offspring of diabetic mothers. Diab. Care. 2000;23:249–254
  38. Lu GC, Rouse DJ, Dubard M, Cliver S, Kimberlin D, Hauth JC. The effect of the increasing prevalence of maternal obesity on perinatal morbidity. Am. J. Obstet. Gynecol. 2001;185:845–849
  39. Pettitt DJ, Knowler WC. Long-term effects of the intrauterine environment, birth weight, and breast-feeding in Pima Indians. Diab. Care. 1998;21(Suppl. 2):B138–B141
  40. Whitaker RC, Dietz WH. Role of the prenatal environment in the development of obesity. J. Pediatr. 1998;132:768–776
  41. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment. The Northwestern University Diabetes Pregnancy Center. Diab. Care. 1998;21(Suppl. 2):B142–B149
  42. Whitaker RC, Dietz WH. Role of the prenatal environment in the development of obesity. J. Pediatr. 1998;132:768–776
  43. Pettitt DJ, Forman MR, Hanson RL, Knowler WC, Bennett PH. Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians. Lancet. 1997;350:166–168
  44. Young TK, Martens PJ, Taback SP, Sellers EA, Dean HJ, Cheang M, et al. Type 2 diabetes mellitus in children: prenatal and early infancy risk factors among native Canadians. Arch. Pediatr. Adolesc. Med. 2002;156:651–655
  45. Rose G. Sick individuals and sick populations. Int. J. Epidemiol. 1985;14:32–38
  46. McKinlay J. A case for refocusing upstream: the political economy of sickness. In:  Enelow A,  Henderson JB editor. Behavioural Aspects of Prevention. Seattle, Washington: American Heart Association; 1975;
  47. King H, Dowd JE. Primary prevention of Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:3–8
  48. Stern M. Kelly West Lecture. Primary prevention of Type II diabetes mellitus. Diab. Care. 1991;14:399–410
  49. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?. J. Int. Med. 2000;247:301–310
  50. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by Tolbutamide and diet regulation. Diabetes. 1980;29:41–49
  51. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–297
  52. Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC The Fasting Hyperglycaemia Study Group. The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism. 1997;46:50–55
  53. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program, Baseline characteristics of the randomized cohort. Diab. Care. 2000;23:1619–1629
  54. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of Type 2 Diabetes mellitus in the diabetes prevention program. Diab. Care. 2003;26:36–47
  55. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M The STOP-NIDDM Trial Research Group. The STOP-NIDDM Trial. An international study on the efficacy of an (-glucosidase inhibitor to prevent Type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary data. Diab. Care. 1998;21:1720–1725
  56. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  57. Hanefeld M, Josse RG, Gomis R, Karasik A, Laakso M, Chiasson JL. Efficacy of acarbose to prevent Type 2 diabetes is different in subgroups of subjects with impaired glucose tolerance: The STOP-NIDDM trial. Diabetologia. 2002;45:104–105
  58. Chiasson J, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose can prevent Type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The STOP-NIDDM trial. Diabetologia. 2002;45:104
  59. Holman RR, North BU, Tunbridge FKE. Possible prevention of Type 2 diabetes with acarbose or metformin. Diab. Med. 2000;17(S1):17
  60. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-year results from the Early Diabetes Intervention Trial. Diab. Med. 2003;20:S15
  61. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin. Trials. 1998;19:217–231
  62. Sjostrom L, Torgerson JS, Hauptman J, Boldrin M. XENDOS (XENical in the prevention of Diabetes in Obese Subjects): a landmark study. In: 9th International Congress on Obesity. Sao Paulo, Brazil. 2002;
  63. M.J. Davies, J.R. Tringham, J. Troughton, K.K. Khunti, Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting, Diab. Med. 21 (5) 403–414.
  64. Ritchie LD, Ganapathy S, Woodward-Lopez G, Gerstein DE, Fleming SE. Prevention of type 2 diabetes in youth: Etiology, promising interventions and recommendations. Pediatr. Diab. 2003;4(4):174–209
  65. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2
  66. Hanefeld M, Josse RG, Gomis R, Karasik A, Laakso M, Chiasson JL. Efficacy of acarbose to prevent Type 2 diabetes is different in subgroups of subjects with impaired glucose tolerance: the STOP-NIDDM trial. Diabetologia. 2002;45:S104–S105
  67. Holman RR, North BU, Tunbridge FKE. Possible prevention of Type 2 diabetes with acarbose or metformin. Diab. Med. 2000;17:S1
  68. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V. Six-year results from the Early Diabetes Intervention Trial. Diab. Med. 2003;20:S15
  69. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin. Trials. 1998;19:217–231
  70. Sjostrom L, Torgerson JS, Hauptman J, Boldrin M. XENDOS (XENical in the prevention of Diabetes in Obese Subjects): a landmark study. In: 9th International Congress on Obesity. Sao Paulo, Brazil. 2002;

PII: S0168-8227(06)00426-8

doi: 10.1016/j.diabres.2006.09.020

Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 317-326 , June 2007

Article Tools

* Image Usage & Resolution